Servicio de Nefrología, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
Int Urol Nephrol. 2011 Jun;43(2):565-9. doi: 10.1007/s11255-010-9748-1. Epub 2010 May 7.
A 43-year-old woman with autosomal-dominant polycystic kidney disease (ADPKD) received octreotide for 12 months, and this was associated with a 6.3% reduction in liver volume, an 8% reduction in total kidney volume and stabilization of renal function. There was also a reduction of cyst size in fibrocystic disease of breast. These data suggest that the cyst fluid accumulation in different organs from patients with ADPKD is a dynamic process which can be reversed by octreotide. This is the first report of a case of simultaneous reduction in hepatic, renal and breast cystic volume with preservation of renal function in a patient with ADPKD receiving octreotide.
一位 43 岁的常染色体显性遗传性多囊肾病（ADPKD）患者接受奥曲肽治疗 12 个月，结果显示其肝体积减少 6.3%，总肾体积减少 8%，肾功能稳定。在纤维囊性乳腺疾病中，囊肿大小也有所减小。这些数据表明，ADPKD 患者不同器官的囊液积聚是一个动态过程，奥曲肽可以使其逆转。这是首例报道奥曲肽治疗 ADPKD 患者时，同时减少肝、肾和乳腺囊肿体积，且保留肾功能的病例。
